Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beijing Quietly Charms Both MNCs And Specialty Biotechs In Effort To Establish China's Bio Valley

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Aiming to carve a leading position in China's nascent biotech industry, Beijing has embarked on a project to grow the industry more than two-fold in three years. Dubbed the "G20 Project," the Beijing Leap-forward Development Program for Biopharmaceutical Industry seeks to transform the capital city into China's hub for biotech R&D and manufacturing

You may also be interested in...



Beijing FDA Gives Quick Nod For H7N9 Rapid Testing Agent

A H7N9 diagnostic testing agent developed by Beijing Kinghawk Pharmaceutical Co. Ltd and Beijing SinoMedgene Technology Co. Ltd. was approved by Beijing FDA under the green channel approval process. The test cuts the time for results to less than three hours, down from six hours.

Merck Unveils $1.5 Billion Expansion In China With New Beijing R&D Center; Plans To Double R&D Team By 2014

While many Big Pharmas are cutting R&D budgets in response to patent cliffs, Merck is investing $1.5 billion in R&D in China, in what could be the largest ever pharma R&D investment in the country.

China's Price Cuts And Antibiotic Limits Weigh On Simcere, But Merck JV Opens Doors

SHANGHAI - Nanjing, China's Simcere Pharmaceutical Group reported a slowdown in sales for the second quarter, pointing to intense competition from the spread of Anhui province's tender model for essential drugs and price cuts on products included in the National Drug Reimbursement List

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC078730

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel